APOLLO BEACH, Fla. and HUNTINGTON, W.Va., Oct. 01, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, and RGEN Inc., a leader in genetic research and innovation (“RGEN”), today announced a strategic partnership to deliver game-changing advancements in the early detection and risk prediction of Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases.
By integrating advanced retinal imaging with clinical-grade DNA genotyping, the two organizations aim to accelerate the development of predictive models and facilitate population-level screening for conditions such as Age-Related Macular Degeneration (AMD), Glaucoma, Diabetic Retinopathy, Complex Dementia, Alzheimer’s Disease, and Parkinson’s Disease.
This collaboration leverages RetinalGenix’s proprietary high-resolution retinal imaging platform alongside RGEN’s CLIA-certified, high-throughput DNA testing capabilities. The dual-pronged diagnostic model aims to capture both phenotypic retinal changes and clinically relevant DNA variants, providing clinicians with actionable insights for early intervention and personalized treatment.
The partnership is believed to represent a major step forward in the field of predictive, preventive, and personalized medicine (PPPM). By combining retinal imaging and DNA testing, the collaboration offers a unique and powerful method for early detection of some of the most impactful chronic systemic and ocular diseases affecting aging populations. This integrated approach holds promise not only for improving patient outcomes but also for reducing the long-term burden on healthcare systems through earlier intervention and disease management.
Key objectives of the partnership include:
- Integrating retinal imaging and genotypic data to develop predictive models for disease risk.
- Identifying novel genetic biomarkers and phenotypic indicators linked to neurodegenerative, systemic and retinal diseases.
- Delivering clinically actionable insights for prevention and personalized care.
- Deploying a scalable, population-based screening platform for chronic diseases.
“Our collaboration allows us to harness the synergies of precision retinal imaging and state-of-the-art genetic analysis,” said Jerry Katzman, MD CEO of RetinalGenix Technologies. “This integrated approach aims to redefine how chronic and ocular diseases are detected and managed in at-risk populations.”
“The combination of RGEN’s clinical-grade genotyping and RetinalGenix’s advanced imaging brings new possibilities for both research and clinical care,” added Jaime Raijman, CEO & Co-founder of RGEN. “Together, we are paving the way for predictive, preventive, and personalized medicine.”
RetinalGenix’s next steps are expected to include the commercial deployment of a combined screening tool in primary care offices, clinics, remote and home monitoring locations and ophthalmology settings, partnerships with healthcare payers to support preventative care coverage, and future expansion of the platform to other age-related and neurodegenerative conditions.
About RetinalGenix Technologies Inc.
RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease, Complex Dementia, and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia.
About RGEN Inc.
RGEN Inc. is a leading innovator in genetic research and testing, providing advanced genomic solutions across clinical, forensic, and consumer applications. Through its CLIA-certified laboratories, RGEN delivers whole genome sequencing, targeted panels, and epigenetic testing with a focus on precision, accuracy, and rapid turnaround. The company’s expertise supports healthcare providers, research institutions, and population-level initiatives seeking to unlock actionable insights into hereditary risk, disease prevention, and personalized wellness.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding delivering advancements in the early detection and risk prediction of Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases, the two organizations accelerating the development of predictive models and facilitating population-level screening for conditions such as Age-Related Macular Degeneration (AMD), Glaucoma, Diabetic Retinopathy, Complex Dementia, Alzheimer’s Disease, and Parkinson’s Disease, the dual-pronged diagnostic model capturing both phenotypic retinal changes and clinically relevant DNA variants, providing clinicians with actionable insights for early intervention and personalized treatment, combining retinal imaging and DNA testing offering a unique and powerful method for early detection of some of the most impactful chronic systemic and ocular diseases affecting aging populations, the integrated approach holding promise not only for improving patient outcomes but also for reducing the long-term burden on healthcare systems through earlier intervention and disease management, integrating retinal imaging and genotypic data to develop predictive models for disease risk, identifying novel genetic biomarkers and phenotypic indicators linked to neurodegenerative, systemic and retinal diseases, delivering clinically actionable insights for prevention and personalized care, deploying a scalable, population-based screening platform for chronic diseases, harnessing the synergies of precision retinal imaging and state-of-the-art genetic analysis, redefining how chronic and ocular diseases are detected and managed in at-risk populations, paving the way for predictive, preventive, and personalized medicine, commercial deployment of a combined screening tool in primary care offices, clinics, remote and home monitoring locations and ophthalmology settings, partnerships with healthcare payers to support preventative care coverage, and future expansion of the platform to other age-related and neurodegenerative conditions and developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully complete research and further development and commercialization of Company products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s products, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Media Contacts:
RetinalGenix Technologies Inc.
Media and Investor Relations
ir@retinalgenix.com
(800) 331-5446
RGEN Inc.
info@rgeninc.com
681-500-RGEN (7436)
